CD274 and neoplasm: These data indicate that a combination of USP2 inhibition and PD-1/PD-L1 blockade potently suppresses tumor growth in vivo, and that the contribution of USP2 inhibition to this effect is dependent on the tumor cell autonomous activity of p53.